Skip to main content

Advertisement

Table 2 Clinicopathological features and outcomes of 196 HER2-negative luminal breast cancer patients

From: Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

  Recurrence No recurrence p value
n 9   187   
Mean age (SD) 55.3 (13.9) 55.9 (12.1) n.s.
Stagea      
   I 2   87   
  IIA or B 4   96   <0.01
  IIIA or B 3   4   
Histology      
  Ductal 7   161   
  Lobular 2   11   n.s.
  Others 0   15   
High nuclear grade 11% (1/9) 4% (7/181) n.s.
High histological grade 22% (2/9) 4% (6/141) n.s.
ERb 100% (9/9) 100% (187/187) n.s.
PRb 67% (6/9) 78% (145/187) n.s.
Mean Ki67 (%) (SD) 37.9 (21.7) 24.1 (18.5) <0.05
(Neo-) adjuvant therapy      
  Endocrine + chemotherapy 9   52   
  Endocrine therapy only 0   127   
  Chemotherapy only 0   1   
  None 0   7   
  1. n.s.: not significant.
  2. adetermined according to pathological findings.
  3. bpercentage of positive (more than 10% of the nuclei of cancer cells) cases.
  4. There were 196 patients with HER2-negative luminal tumours who underwent surgery during the 18-month period starting in April 2010. Compared to the 114 described above, this population includes relatively low-risk patients, i.e. 45% of the 196 patients had Stage I while all of the 114 had stage II or III disease. (Only 31% of this population received NAC plus endocrine therapy).